Which has higher earnings and valuation, EVLO or GNCA?

Genocea Biosciences has higher revenue and earnings than Evelo Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evelo Biosciences N/A N/A -$114.53M -$4.21 N/A Genocea Biosciences $1.91M 0.00 -$33.20M -$0.61 N/A

Is EVLO or GNCA more profitable?

Evelo Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Evelo Biosciences N/A N/A N/A Genocea Biosciences N/A -182.88% -62.76%

Do analysts rate EVLO or ADTX?

Given Evelo Biosciences' higher possible upside, research analysts plainly believe Evelo Biosciences is more favorable than Aditxt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, EVLO or ADTX?

Aditxt has higher revenue and earnings than Evelo Biosciences. Aditxt is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evelo Biosciences N/A N/A -$114.53M -$4.21 N/A Aditxt $14.34K 0.39 -$41.71M -$100.79 thousand N/A

Which has higher valuation and earnings, EVLO or ARDS?

Evelo Biosciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evelo Biosciences N/A N/A -$114.53M -$4.21 N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.31 0.00

Is EVLO or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Evelo Biosciences N/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A

Does the media refer more to EVLO or ARDS?

In the previous week, Evelo Biosciences and Evelo Biosciences both had 1 articles in the media. Evelo Biosciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aridis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, GNCAQ or EVLO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Evelo Biosciences N/A N/A -$114.53M -$4.21 N/A

Is GNCAQ or EVLO more profitable?

Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A N/A N/A Evelo Biosciences N/A N/A N/A

Which has better earnings and valuation, EVLO or CMRA?

Comera Life Sciences has higher revenue and earnings than Evelo Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evelo Biosciences N/A N/A -$114.53M -$4.21 N/A Comera Life Sciences $1.00M 0.00 -$18M -$0.18 N/A

Is EVLO or CMRA more profitable?

Company Net Margins Return on Equity Return on Assets Evelo Biosciences N/A N/A N/A Comera Life Sciences N/A N/A N/A

Evelo Biosciences (EVLO) Competitors

Compare

EVLO vs. GNCA, ADTX, ARDS, GNCAQ, and CMRA

Should you buy Evelo Biosciences stock or one of its competitors? Evelo Biosciences's main competitors and comparable companies include Genocea Biosciences (GNCA), Aditxt (ADTX), Aridis Pharmaceuticals (ARDS), Genocea Biosciences (GNCAQ), and Comera Life Sciences (CMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Evelo Biosciences compare to Genocea Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Genocea Biosciences has higher revenue and earnings than Evelo Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$4.21	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

In the previous week, Evelo Biosciences had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Genocea Biosciences. Evelo Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Evelo Biosciences	Neutral
Genocea Biosciences	Neutral

Evelo Biosciences has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Evelo Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Genocea Biosciences	N/A	-182.88%	-62.76%

Summary

Evelo Biosciences and Genocea Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Evelo Biosciences compare to Aditxt?

Evelo Biosciences (NASDAQ:EVLO) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Evelo Biosciences has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Given Evelo Biosciences' higher possible upside, research analysts plainly believe Evelo Biosciences is more favorable than Aditxt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evelo Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evelo Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Evelo Biosciences' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Aditxt	-360,152.50%	-374.60%	-105.93%

Aditxt has higher revenue and earnings than Evelo Biosciences. Aditxt is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$4.21	N/A
Aditxt	$14.34K	0.39	-$41.71M	-$100.79 thousand	N/A

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Evelo Biosciences had 1 more articles in the media than Aditxt. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Aditxt. Evelo Biosciences' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company	Overall Sentiment
Evelo Biosciences	Neutral
Aditxt	Neutral

Summary

Evelo Biosciences beats Aditxt on 8 of the 13 factors compared between the two stocks.

How does Evelo Biosciences compare to Aridis Pharmaceuticals?

Evelo Biosciences (NASDAQ:EVLO) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Evelo Biosciences has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.66, indicating that its share price is 4,866% more volatile than the broader market.

In the previous week, Evelo Biosciences and Evelo Biosciences both had 1 articles in the media. Evelo Biosciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aridis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evelo Biosciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$4.21	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	0.00

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	N/A

Summary

Aridis Pharmaceuticals beats Evelo Biosciences on 6 of the 6 factors compared between the two stocks.

How does Evelo Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Evelo Biosciences had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Genocea Biosciences. Genocea Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Evelo Biosciences	Neutral

Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Evelo Biosciences	N/A	N/A	-$114.53M	-$4.21	N/A

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Evelo Biosciences	N/A	N/A	N/A

0.3% of Evelo Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Evelo Biosciences beats Genocea Biosciences on 3 of the 5 factors compared between the two stocks.

How does Evelo Biosciences compare to Comera Life Sciences?

Evelo Biosciences (NASDAQ:EVLO) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Comera Life Sciences	N/A	N/A	N/A

Evelo Biosciences has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Comera Life Sciences has higher revenue and earnings than Evelo Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$4.21	N/A
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.18	N/A

In the previous week, Evelo Biosciences had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Comera Life Sciences. Evelo Biosciences' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company	Overall Sentiment
Evelo Biosciences	Neutral
Comera Life Sciences	Neutral

Summary

Evelo Biosciences and Comera Life Sciences tied by winning 4 of the 8 factors compared between the two stocks.

Get Evelo Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVLO vs. The Competition

Export

Metric	Evelo Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.27	273.29	25.25
Price / Sales	N/A	754.88	623.67	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	N/A	12.33	12.92	6.14
Net Income	-$114.53M	$2.82B	$3.47B	$349.01M

Evelo Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	$2K	N/A	N/A	120
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
ADTX Aditxt	0.174 of 5 stars	$0.01 +5.5%	N/A	-100.0%	$5K	$14.34K	N/A	60	Gap Down
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	+0.0%	$5K	N/A	0.00	30
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	$5K	N/A	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVLO) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evelo Biosciences (EVLO) Competitors

EVLO vs. GNCA, ADTX, ARDS, GNCAQ, and CMRA

How does Evelo Biosciences compare to Genocea Biosciences?

Summary

How does Evelo Biosciences compare to Aditxt?

Summary

How does Evelo Biosciences compare to Aridis Pharmaceuticals?

Summary

How does Evelo Biosciences compare to Genocea Biosciences?

Summary

How does Evelo Biosciences compare to Comera Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVLO vs. The Competition

Evelo Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evelo Biosciences (EVLO) Competitors

EVLO vs. GNCA, ADTX, ARDS, GNCAQ, and CMRA

How does Evelo Biosciences compare to Genocea Biosciences?

Which has higher earnings and valuation, EVLO or GNCA?

Does the media refer more to EVLO or GNCA?

Which has more volatility and risk, EVLO or GNCA?

Do institutionals & insiders hold more shares of EVLO or GNCA?

Is EVLO or GNCA more profitable?

Summary

How does Evelo Biosciences compare to Aditxt?

Which has more volatility & risk, EVLO or ADTX?

Do analysts rate EVLO or ADTX?

Is EVLO or ADTX more profitable?

Which has stronger earnings and valuation, EVLO or ADTX?

Do institutionals & insiders believe in EVLO or ADTX?

Does the media prefer EVLO or ADTX?

Summary

How does Evelo Biosciences compare to Aridis Pharmaceuticals?

Do institutionals & insiders believe in EVLO or ARDS?

Which has more volatility and risk, EVLO or ARDS?

Does the media refer more to EVLO or ARDS?

Which has higher valuation and earnings, EVLO or ARDS?

Is EVLO or ARDS more profitable?

Summary

How does Evelo Biosciences compare to Genocea Biosciences?

Does the media favor GNCAQ or EVLO?

Which has more risk & volatility, GNCAQ or EVLO?

Which has stronger valuation & earnings, GNCAQ or EVLO?

Is GNCAQ or EVLO more profitable?

Do institutionals & insiders believe in GNCAQ or EVLO?

Summary

How does Evelo Biosciences compare to Comera Life Sciences?

Do institutionals & insiders believe in EVLO or CMRA?

Is EVLO or CMRA more profitable?

Which has more volatility & risk, EVLO or CMRA?

Which has better earnings and valuation, EVLO or CMRA?

Does the media prefer EVLO or CMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVLO vs. The Competition

Evelo Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools